Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | HTR7 | P34969 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1127764 | 0.98 | PAOX (0.67) | PAOXCYP1A2MAPK1SMN1; SMN2HTR7 | |
| SCHEMBL26495613 | 0.98 | PAOX (0.72) | PAOXCYP1A2MAPK1SMN1; SMN2HTR7 | |
| SCHEMBL17268199 | 0.98 | PAOX (0.72) | PAOXCYP1A2MAPK1SMN1; SMN2HTR7 | |
| Bromide SCHEMBL11737136 | 0.98 | PAOX (0.67) | PAOXCYP1A2MAPK1SMN1; SMN2HTR7 | |
| SCHEMBL4009221 | 0.98 | PAOX (0.72) | PAOXCYP1A2MAPK1SMN1; SMN2HTR7 | |
| SCHEMBL4681280 | 0.94 | SMN1; SMN2 (0.67) | PAOXCYP1A2MAPK1SMN1; SMN2HTR7 | |
| Hydrochloric Acid SCHEMBL1128155 | 0.92 | SMN1; SMN2 (0.64) | PAOXCYP1A2MAPK1SMN1; SMN2HTR7 | |
| Hydrochloric Acid SCHEMBL1127753 | 0.92 | SMN1; SMN2 (0.64) | PAOXCYP1A2MAPK1SMN1; SMN2HTR7 | |
| SCHEMBL8380184 | 0.91 | CYP1A2 (0.68) | PAOXCYP1A2MAPK1SMN1; SMN2HTR7 | |
| SCHEMBL26180910 | 0.91 | CYP1A2 (0.68) | PAOXCYP1A2MAPK1SMN1; SMN2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2968145-A1 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS | Mallinckrodt LLC (US) | 2016-01-20 | — | — | EP | claimed |
| CN-105188675-A | Modified docetaxel liposome formulations | MALLINCKRODT LLC | 2015-12-23 | — | — | CN | claimed |
| WO-2014160392-A1 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS | MALLINCKRODT LLC (US) | 2014-10-02 | — | — | WO | claimed |
| WO-2023196444-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-RE49594-E1 | Apelin receptor (APJ) agonists and uses thereof | RESEARCH TRIANGLE INSTITUTE (US) | 2023-08-01 | — | — | US | disclosed |
| US-11535630-B2 | Apelin receptor (APJ) agonists and uses thereof | RESEARCH TRIANGLE INSTITUTE (US) | 2022-12-27 | — | — | US | disclosed |
| US-10954247-B2 | Apelin receptor (APJ) agonists and uses thereof | RESEARCH TRIANGLE INSTITUTE (NC) | 2021-03-23 | — | — | US | disclosed |
| US-20210070767-A1 | APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF | RESEARCH TRIANGLE INSTITUTE | 2021-03-11 | — | — | US | disclosed |
| CN-104622809-B | The drug of modification for elaioplast nanometer particle | 英属哥伦比亚大学 | 2019-04-19 | — | — | CN | disclosed |
| EP-3386976-A1 | IMPROVED APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF | Research Triangle Institute, International (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20120237591-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2012-09-20 | — | — | US | disclosed |
| US-20110165225-A1 | Modified Drugs for Use in Liposomal Nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-07-07 | — | — | US | disclosed |
| US-20110165225-A1 | Modified Drugs for Use in Liposomal Nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-07-07 | — | — | US | disclosed |
| CN-102105135-A | Modified drugs for liposomal nanoparticles | UNIV BRITISH COLUMBIA | 2011-06-22 | — | — | CN | disclosed |
| WO-2009141738-A2 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2009-11-26 | — | — | WO | disclosed |
| US-20080275028-A1 | Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof | SIENA BIOTECH S.P.A. (IT) | 2008-11-06 | — | — | US | disclosed |
| CN-101018774-A | Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof | SIENA BIOTECH SPA (IT) | 2007-08-15 | — | — | CN | disclosed |
| EP-1778658-A2 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | Siena Biotech S.p.A. (IT) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006008133-A2 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | SIENA BIOTECH S.P.A. (IT) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535630-B2 | Apelin receptor (APJ) agonists and uses thereof | APLNR, AP1G1, APMAP | PAOX 1081/4885CYP1A2 4586/4885MAPK1 4029/4885 |
| US-20110165225-A1 | Modified Drugs for Use in Liposomal Nanoparticles | ABCB11, SLC47A1, ABCB1 | PAOX 2984/4885CYP1A2 4232/4885MAPK1 2101/4885 |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | PLTP, LNPEP, PLIN3 | PAOX 1159/4885CYP1A2 4878/4885MAPK1 4305/4885 |
| US-20210070767-A1 | APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF | APLNR, AP1G1, APMAP | PAOX 1081/4885CYP1A2 4586/4885MAPK1 4029/4885 |
| US-20120237591-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, ABCB1, SLC43A1 | PAOX 2515/4885CYP1A2 2738/4885MAPK1 2196/4885 |
| US-20080275028-A1 | Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof | CHRNA7, CHRNA5, CHRNA1 | PAOX 2394/4885CYP1A2 1878/4885MAPK1 1753/4885 |
| US-10954247-B2 | Apelin receptor (APJ) agonists and uses thereof | APLNR, AP1G1, APMAP | PAOX 1081/4885CYP1A2 4586/4885MAPK1 4029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.